Introduction: Who Should Undergo Diagnostics and When

Knowing when to seek diagnostic testing for rectal cancer is an important part of protecting your health. If you experience certain warning signs, it’s advisable to talk with your doctor as soon as possible. Common symptoms that should prompt a medical evaluation include blood in your stool, which may appear bright red or very dark, and changes in your bowel habits such as diarrhea, constipation, or a more frequent need to pass stool^[1]. You might also notice that your stool looks narrower than usual or has a different shape, or you may feel that your bowel doesn’t empty completely after a bowel movement^[3].

Other signs that warrant attention include ongoing abdominal discomfort such as frequent gas pains, bloating, fullness, or cramping. Some people experience unexplained weight loss, a change in appetite, or persistent feelings of weakness and tiredness^[5]. It’s important to understand that these symptoms don’t always mean you have rectal cancer—they can be caused by many other conditions, including hemorrhoids or other digestive problems^[8]. However, because early detection dramatically improves treatment outcomes, any of these changes should be discussed with your healthcare provider.

Even if you don’t have symptoms, screening is recommended for adults starting at age 45. This age was recently lowered from 50 because experts noticed a trend toward earlier diagnosis in younger people^[8]. The reason screening matters so much is that most rectal cancers start as small growths called polyps, which are clumps of abnormal cells. It can take 10 to 15 years for a polyp to develop into cancer, which gives doctors a long window to find and remove these growths before they become dangerous^[2].

Certain people face higher risk and may need to start screening earlier or undergo more frequent testing. If you have a biological family member—such as a parent, sibling, or child—who has been diagnosed with rectal or colon cancer, your own risk almost doubles^[2]. Other risk factors include having a personal history of colorectal cancer, ovarian cancer, or high-risk polyps that are 1 centimeter or larger. If you have inflammatory bowel disease such as ulcerative colitis or Crohn’s disease for 8 years or more, you also face increased risk^[3].

Inherited genetic conditions also raise your risk significantly. These include Lynch syndrome (also called hereditary nonpolyposis colorectal cancer), familial adenomatous polyposis (FAP), and several other rare inherited disorders. If you know that these conditions run in your family, talk to your doctor about genetic counseling and when you should begin screening^[3].

Statistically, people who are Black are more likely to develop rectal cancer, though researchers don’t yet fully understand why. Other risk factors that can be changed include obesity, smoking tobacco, and drinking three or more alcoholic drinks per day^[3]. Men are slightly more likely to develop rectal cancer than women, and the average age of diagnosis is 63, though increasing age is a main risk factor for most cancers^[2].

Classic Diagnostic Methods

Once you and your doctor decide that diagnostic testing is needed, several methods can be used to identify rectal cancer and distinguish it from other conditions. The diagnostic process typically starts with a careful medical history and physical examination. Your doctor will ask about your symptoms, family history, past illnesses, and overall health habits^[5].

A digital rectal exam (DRE) is often one of the first steps. During this exam, your doctor inserts a lubricated, gloved finger into the lower part of your rectum to feel for lumps or anything else that seems unusual. In women, the vagina may also be examined. While this exam may feel uncomfortable, it’s quick and can provide valuable information about whether further testing is needed^[5].

If your doctor finds something concerning during the physical exam, or if you have symptoms, the next step is usually an endoscopy examination. A colonoscopy is considered the gold standard for diagnosing rectal cancer. This procedure uses a long, flexible tube with a camera at the end, called a colonoscope, to show the inside of your colon and rectum. Before the procedure, you’ll need to do a bowel cleansing the day before to clear out your intestines^[11]. During the colonoscopy, your doctor can look for polyps and areas of abnormal appearance. Medicines are given before and during the procedure to keep you comfortable^[11].

An office-based proctoscopy or sigmoidoscopy can also be performed to look into the rectum with a scope, sometimes with a camera attached. This may be done right in your doctor’s office. For rectal cancer specifically, a rigid sigmoidoscopy is particularly useful because it can accurately measure the distance from the tumor to the anal verge, which is the opening of your anus. This measurement is important because the rectum measures between 10 to 15 centimeters from the anal verge, and knowing exactly where the tumor is located helps doctors plan the best treatment^[8][17].

If areas of concern are found during any of these procedures, your doctor will perform a biopsy. This means taking a very small sample of tissue from inside the rectum using special cutting tools that pass through the colonoscope. The tissue sample is then sent to a laboratory where a specialist called a pathologist examines it under a microscope to look for cancer cells^[11]. Special tests on the tissue can give more detailed information about the cancer cells, which helps your healthcare team create a treatment plan tailored to your specific situation.

After a diagnosis of rectal cancer is confirmed through biopsy, additional imaging tests help determine whether the cancer has spread and how advanced it is. This process is called staging. A complete blood count (CBC) reports the numbers of different types of cells in your blood and can show if you have anemia from bleeding^[11]. A blood test for carcinoembryonic antigen (CEA) looks for a certain protein that some rectal cancers release. If your CEA level is high before treatment, doctors can track it during and after treatment to see how well therapy is working^[8].

Computed tomography (CT) scans use X-rays and computers to create detailed pictures of the inside of your body. These scans can show whether cancer has spread to the liver, lungs, or other organs. A CT scan of your chest, abdomen, and pelvis is commonly performed as part of the staging process^[11]. Magnetic resonance imaging (MRI) is especially useful for rectal cancer because it provides excellent images of the soft tissues in the pelvis. An MRI can accurately determine how deeply the tumor has grown into the rectal wall and whether nearby lymph nodes contain cancer cells^[4].

Endorectal ultrasound (also called transrectal ultrasound) is another imaging technique that helps determine local tumor extension and whether lymph nodes near the rectum are involved. During this test, a small ultrasound probe is inserted into the rectum to create images of the rectal wall and surrounding structures^[4]. Positron emission tomography (PET) scans may also be used to look for cancer that has spread to distant parts of the body. These scans detect areas of high metabolic activity, which can indicate cancer^[8].

The stage of your cancer is one of the most important factors affecting your treatment options and prognosis. Staging takes into account how far the cancer has grown through the rectal wall, whether it has spread to nearby lymph nodes, and whether it has spread to distant organs. Your tumor’s location in the rectum also matters because the distance from the anal sphincter muscles affects whether sphincter-sparing surgery is possible^[17]. Other factors that influence outcomes include whether the tumor is causing a blockage or has created a hole in the rectum, as well as your general health and ability to tolerate treatment^[8].

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments to find better ways to help patients with rectal cancer. If you’re considering participating in a clinical trial, you’ll need to undergo specific diagnostic tests to determine whether you qualify. These tests serve as standard criteria for enrolling patients and ensure that the trial includes people who are most likely to benefit from the experimental treatment being studied.

The basic diagnostic workup for clinical trial participation typically mirrors the standard diagnostic process. You’ll need a confirmed diagnosis of rectal cancer through biopsy, with tissue examination by a pathologist. The pathology report will describe the type of cancer cells and their characteristics, which is essential information for trial eligibility^[11]. Many trials require that your cancer be staged using imaging tests such as CT scans, MRI, and sometimes PET scans to establish the extent of disease before treatment begins.

Lab tests for clinical trials often include more detailed analysis of your cancer’s molecular characteristics. For example, researchers increasingly look at specific genetic mutations in cancer cells to determine which treatments might work best. Testing for microsatellite instability (MSI) and mismatch repair (MMR) deficiency has become standard, as up to 13% of sporadic rectal cancers show these features^[4]. Cancers with high microsatellite instability may respond differently to certain therapies, including newer immunotherapy treatments.

Blood tests form another important component of trial screening. Beyond the standard complete blood count and CEA levels, trials may require tests to check your liver function, kidney function, and overall organ health. These tests ensure that your body can safely handle the experimental treatment. Many trials exclude patients whose blood counts are too low or whose organs aren’t functioning well enough, because the treatment might be too risky for them.

Imaging requirements for clinical trials can be quite specific. For rectal cancer trials, high-quality MRI or endorectal ultrasound is often required to precisely measure tumor size and location, assess depth of invasion into the rectal wall, and evaluate lymph node involvement^[4]. These baseline measurements are crucial because researchers need to track changes in tumor size during the study to determine whether the experimental treatment is working. Some trials mandate that imaging be performed using specific techniques or equipment to ensure consistency across all participants.

Trials testing new targeted therapies or immunotherapies often require additional molecular testing of your tumor tissue. This might include looking for specific genetic mutations such as KRAS, NRAS, or BRAF, or testing for proteins like HER2 or PD-L1 expression. These biomarkers help identify which patients are most likely to respond to particular treatments. The tissue sample from your original biopsy is usually sufficient for these tests, though occasionally a new biopsy may be needed if more tissue is required.

Performance status evaluation is another standard requirement for trial participation. Doctors use scales like the Eastern Cooperative Oncology Group (ECOG) performance status or the Karnofsky performance scale to measure how well you can carry out daily activities. Most trials accept only patients who are relatively healthy and active, because very ill patients might not tolerate experimental treatments well or might have outcomes influenced more by their overall health than by the treatment being studied.

Documentation of previous treatments is essential for clinical trial screening. Trials often specify whether you must be newly diagnosed with no prior treatment, or whether you must have already tried certain standard treatments. Your medical records will be reviewed carefully to ensure you meet these criteria. Some trials exclude patients who have received certain types of chemotherapy or radiation therapy, while others specifically seek patients who have already undergone standard treatments.

Throughout a clinical trial, you’ll undergo frequent diagnostic testing to monitor your response to treatment and watch for side effects. These repeated tests—which may include blood work, imaging scans, and sometimes additional biopsies—are built into the trial protocol. The close monitoring means that any problems can be detected early, but it also requires a significant time commitment from participants. Understanding these requirements upfront helps you decide whether trial participation fits with your life circumstances.